Evaluating the Long-term Safety and Tolerability of Imatinib in Patients With Lymphangioleiomyomatosis (LAM) — StellaPhase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations(2 sites)
United States
Columbia University Irving Medical Center, New York, New York Medical University of South Carolina, Charleston, South Carolina Age range
18 Years – 64 Years
Last updated January 2026